Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease

Metabolism: Clinical and Experimental

Volumn 63, Issue 1, 2014, Pages 20-31

  Tomaschitz, Andreas ^a,b   Ritz, Eberhard ^c   Pieske, Burkert ^a   Rus Machan, Jutta ^b   Kienreich, Katharina ^a   Verheyen, Nicolas ^a   Gaksch, Martin ^a   Grübler, Martin ^a   Fahrleitner Pammer, Astrid ^a   Mrak, Peter ^d   Toplak, Hermann ^a   Kraigher Krainer, Elisabeth ^a   März, Winfried ^a,e,f   Pilz, Stefan ^a,g  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Specialist Clinic for Rehabilitation PV Bad Aussee   (Austria)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f SYNLAB ACADEMY   (Germany)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aldosterone; Aldosteronism; Hyperparathyroidism; Parathyroid hormone

Indexed keywords

ALDOSTERONE; CALCIUM; KLOTHO PROTEIN; PARATHYROID HORMONE; SPIRONOLACTONE; VITAMIN D; VITAMIN D RECEPTOR;

ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE DISEASE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; GLUCOSE METABOLISM; HEART MUSCLE FIBROSIS; HUMAN; HYPERALDOSTERONISM; HYPOCALCEMIA; HYPOMAGNESEMIA; METABOLIC DISORDER; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; ZONA GLOMERULOSA;

EID: 84890128111     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.08.016     Document Type: Review

References (134)

1. J. Perk, G. De Backer, and H. Gohlke European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Atherosclerosis 223 2012 1 68
2. A. Tomaschitz, E. Ritz, and B. Pieske Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease Cardiovasc Res 94 2012 10 19
3. J.S. Williams Evolving research in nongenomic actions of aldosterone Curr Opin Endocrinol Diabetes Obes 20 2013 198 203
4. M. Lombes, N. Alfaidy, and E. Eugene Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart Circulation 92 1995 175 182
5. P. Milliez, X. Girerd, and P.F. Plouin Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J Am Coll Cardiol 45 2005 1243 1248
6. M. Abe, M. Hamada, and H. Matsuoka Myocardial scintigraphic characteristics in patients with primary aldosteronism Hypertension 23 1994 I164 I167
7. G.P. Rossi, A. Sacchetto, and P. Visentin Changes in left ventricular anatomy and function in hypertension and primary aldosteronism Hypertension 27 1996 1039 1045
8. Y. Shigematsu, M. Hamada, and H. Okayama Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism Hypertension 29 1997 723 727
9. A. Tomaschitz, S. Pilz, and W. März Arterial hypertension and cardiovascular disease - absolute aldosterone excess is the tip of the iceberg J Lab Med 35 2011 147 151
10. A. Tomaschitz, S. Pilz, and E. Ritz Relationship between plasma aldosterone concentration and soluble cellular adhesion molecules in patients referred to coronary angiography Exp Clin Endocrinol Diabetes 119 2011 649 655
11. K. Swedberg, P. Eneroth, J. Kjekshus, and L. Wilhelmsen Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group Circulation 82 1990 1730 1736
12. A. Tomaschitz, S. Pilz, and E. Ritz Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study Eur Heart J 31 2010 1237 1247
13. A. Tomaschitz, S. Pilz, and E. Ritz Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study Am J Kidney Dis 57 2011 403 414
14. F. Ivanes, S. Susen, and F. Mouquet Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure Eur Heart J 33 2012 191 202
15. C. Drechsler, E. Ritz, and A. Tomaschitz Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients Eur Heart J 34 2013 578 587
16. A. Tomaschitz, S. Pilz, and B. Pieske Circulating aldosterone and mortality in female nursing home residents Exp Gerontol 48 2013 313 318
17. A. Tomaschitz, and S. Pilz Aldosterone to renin ratio - a reliable screening tool for primary aldosteronism? Horm Metab Res 42 2010 382 391
18. P.M. Jansen, W.J. Frenkel, and B.J. van den Born Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension J Hypertens 31 2013 404 413
19. B.C. Huber, S. Brunner, and A. Segeth Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart Cardiovasc Res 90 2011 529 537
20. M. Di Monaco, F. Vallero, and R. Di Monaco Primary hyperparathyroidism in elderly patients with hip fracture J Bone Miner Metab 22 2004 491 495
21. E. Osto, F. Fallo, and M.R. Pelizzo Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy Circulation 126 2012 1031 1039
22. M.H. Christensen, S.N. Dankel, and Y. Nordbo Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue PLoS One 6 2011 e20481
23. E.G. Almqvist, A.G. Bondeson, and L. Bondeson Factors influencing insulin sensitivity in patients with mild primary hyperparathyroidism before and after parathyroidectomy Scand J Clin Lab Invest 72 2012 92 99
24. S. Iwata, M.D. Walker, and M.R. Di Tullio Aortic valve calcification in mild primary hyperparathyroidism J Clin Endocrinol Metab 97 2012 132 137
25. G. Schillaci, G. Pucci, and M. Pirro Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism Atherosclerosis 218 2011 96 101
26. E.G. Almqvist, A.G. Bondeson, L. Bondeson, and J. Svensson Increased markers of inflammation and endothelial dysfunction in patients with mild primary hyperparathyroidism Scand J Clin Lab Invest 71 2011 139 144
27. A. Heyliger, V. Tangpricha, C. Weber, and J. Sharma Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism Surgery 146 2009 1042 1047
28. S.J. Silverberg, E.M. Lewiecki, and L. Mosekilde Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop J Clin Endocrinol Metab 94 2009 351 365
29. S. Ljunghall, S. Jakobsson, and C. Joborn Longitudinal studies of mild primary hyperparathyroidism J Bone Miner Res 6 Suppl 2 1991 S111 S116 [discussion S21-4]
30. E. Kamycheva, J. Sundsfjord, and R. Jorde Serum parathyroid hormone level is associated with body mass index. The 5th Tromso study Eur J Endocrinol 151 2004 167 172
31. I.L. Nilsson, J. Aberg, J. Rastad, and L. Lind Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism - effects of parathyroidectomy Surgery 128 2000 895 902
32. R. Alemzadeh, and J. Kichler Parathyroid hormone is associated with biomarkers of insulin resistance and inflammation, independent of vitamin D status, in obese adolescents Metab Syndr Relat Disord 10 2012 422 429
33. L. Morfis, P. Smerdely, and L.G. Howes Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures J Hypertens 15 1997 1271 1276
34. S. Pilz, A. Tomaschitz, and C. Drechsler Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography Eur Heart J 31 2010 1591 1598
35. E. Hagstrom, P. Hellman, and T.E. Larsson Plasma parathyroid hormone and the risk of cardiovascular mortality in the community Circulation 119 2009 2765 2771
36. A.J. van Ballegooijen, I. Reinders, and M. Visser Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study J Clin Endocrinol Metab 98 2013 E638 E645
37. N. Verheyen, S. Pilz, and K. Eller Cinacalcet hydrochloride for the treatment of hyperparathyroidism Expert Opin Pharmacother 14 2013 793 806
38. S.A. Atlas The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition J Manag Care Pharm 13 2007 9 20
39. M.H. de Borst, M.G. Vervloet, P.M. ter Wee, and G. Navis Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease J Am Soc Nephrol 22 2011 1603 1609
40. A. Vaidya, and J.S. Williams The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes Metabolism 61 2012 450 458
41. Y.C. Li, J. Kong, and M. Wei 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system J Clin Invest 110 2002 229 238
42. J. Kong, and Y.C. Li Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice Am J Physiol Regul Integr Comp Physiol 285 2003 R255 R261
43. M. Kuro-o, Y. Matsumura, and H. Aizawa Mutation of the mouse klotho gene leads to a syndrome resembling ageing Nature 390 1997 45 51
44. A. Tomaschitz, S. Pilz, and E. Ritz Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure Eur Heart J 32 2011 2642 2649
45. J.P. Forman, J.B. Scott, and K. Ng Effect of vitamin D supplementation on blood pressure in blacks Hypertension 61 2013 779 785
46. A. Vaidya, B. Sun, and C. Larson Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: an interventional study J Clin Endocrinol Metab 97 2012 2456 2465
47. A. Tomaschitz, S. Pilz, and E. Ritz Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study Clin Chim Acta 411 2010 1354 1360
48. J. Lundqvist, K. Wikvall, and M. Norlin Vitamin D-mediated regulation of CYP21A2 transcription - a novel mechanism for vitamin D action Biochim Biophys Acta 2012 1820 1553 1559
49. J. Lundqvist, M. Norlin, and K. Wikvall 1alpha,25-Dihydroxyvitamin D3 affects hormone production and expression of steroidogenic enzymes in human adrenocortical NCI-H295R cells Biochim Biophys Acta 2010 1801 1056 1062
50. R.U. Simpson, S.H. Hershey, and K.A. Nibbelink Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse J Steroid Biochem Mol Biol 103 2007 521 524
51. S. Santos Rde, V.A. Vieira da Costa, and L.M. Vianna Cholecalciferol treatment changes urinary sodium-potassium ratio and plasma aldosterone of spontaneously hypertensive rats Clin Chim Acta 376 2007 253 254
52. D. Carrara, M. Bernini, and A. Bacca Cholecalciferol administration blunts the systemic renin-angiotensin system in essential hypertensives with hypovitaminosis D J Renin Angiotensin Aldosterone Syst 2013 10.1177/ 1470320312471149
53. A. Vaidya, B. Sun, and J.P. Forman The Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians Clin Endocrinol 74 2011 783 790
54. A. Vaidya, J.P. Forman, and P.N. Hopkins 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians J Renin Angiotensin Aldosterone Syst 12 2011 311 319
55. H. Kurosu, M. Yamamoto, and J.D. Clark Suppression of aging in mice by the hormone Klotho Science 309 2005 1829 1833
56. S.S. Fischer, D.S. Kempe, and C.B. Leibrock Hyperaldosteronism in Klotho-deficient mice Am J Physiol Renal Physiol 299 2010 F1171 F1177
57. J. Voelkl, I. Alesutan, and C.B. Leibrock Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice J Clin Invest 123 2013 812 822
58. C. Tang, G. Pathare, and D. Michael Downregulation of Klotho expression by dehydration Am J Physiol Renal Physiol 301 2011 F745 F750
59. N. Queisser, P.I. Oteiza, and H. Stopper Aldosterone induces oxidative stress, oxidative DNA damage and NF-kappaB-activation in kidney tubule cells Mol Carcinog 50 2011 123 135
60. F. Lang, E. Ritz, J. Voelkl, and I. Alesutan Vascular calcification - is aldosterone a culprit? Nephrol Dial Transplant 28 2013 1080 1084
61. P. Bjorklund, T. Krajisnik, and G. Akerstrom Type I membrane klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism J Clin Endocrinol Metab 93 2008 4152 4157
62. J. Latus, R. Lehmann, and M. Roesel Analysis of alpha-klotho, fibroblast growth factor-, vitamin-D and calcium-sensing receptor in 70 patients with secondary hyperparathyroidism Kidney Blood Press Res 37 2013 84 94
63. R.D. Semba, A.R. Cappola, and K. Sun Plasma klotho and cardiovascular disease in adults J Am Geriatr Soc 59 2011 1596 1601
64. Y. Brandenburger, E.D. Kennedy, and C.P. Python Possible role for mitochondrial calcium in angiotensin II- and potassium-stimulated steroidogenesis in bovine adrenal glomerulosa cells Endocrinology 137 1996 5544 5551
65. A. Spat, and L. Hunyady Control of aldosterone secretion: a model for convergence in cellular signaling pathways Physiol Rev 84 2004 489 539
66. N. Cherradi, M.F. Rossier, M.B. Vallotton, and A.M. Capponi Calcium stimulates intramitochondrial cholesterol transfer in bovine adrenal glomerulosa cells J Biol Chem 271 1996 25971 25975
67. C.M. Isales, P.Q. Barrett, and M. Brines Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell Endocrinology 129 1991 489 495
68. K. Olgaard, E. Lewin, and S. Bro Enhancement of the stimulatory effect of calcium on aldosterone secretion by parathyroid hormone Miner Electrolyte Metab 20 1994 309 314
69. P. Urena, X.F. Kong, and A.B. Abou-Samra Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues Endocrinology 133 1993 617 623
70. J. Rosenberg, M. Pines, and S. Hurwitz Response of adrenal cells to parathyroid hormone stimulation J Endocrinol 112 1987 431 437
71. H.N. Hulter, J.C. Melby, J.C. Peterson, and C.R. Cooke Chronic continuous PTH infusion results in hypertension in normal subjects J Clin Hypertens 2 1986 360 370
72. G. Mazzocchi, F. Aragona, L.K. Malendowicz, and G.G. Nussdorfer PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells Am J Physiol Endocrinol Metab 280 2001 E209 E213
73. F. Fallo, S. Rocco, and U. Pagotto Aldosterone and pressor responses to angiotensin II in primary hyperparathyroidism J Hypertens Suppl 7 1989 S192 S193
74. C. Maniero, A. Fassina, and V. Guzzardo Primary hyperparathyroidism with concurrent primary aldosteronism Hypertension 58 2011 341 346
75. M. Rizk-Rabin, G. Assie, and F. Rene-Corail Differential expression of parathyroid hormone-related protein in adrenocortical tumors: autocrine/paracrine effects on the growth and signaling pathways in H295R cells Cancer Epidemiol Biomarkers Prev 17 2008 2275 2285
76. C. Gennari, R. Nami, and S. Gonnelli Hypertension and primary hyperparathyroidism: the role of adrenergic and renin-angiotensin-aldosterone systems Miner Electrolyte Metab 21 1995 77 81
77. L. Kovacs, M.I. Goth, and I. Szabolcs The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism Eur J Endocrinol 138 1998 543 547
78. J.R. Sowers, A. Whaley-Connell, and M. Epstein Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension Ann Intern Med 150 2009 776 783
79. F. Fallo, F. Veglio, and C. Bertello Prevalence and characteristics of the metabolic syndrome in primary aldosteronism J Clin Endocrinol Metab 91 2006 454 459
80. E. Kumagai, H. Adachi, and D.R. Jacobs Jr. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population Hypertension 58 2011 1043 1048
81. J. Matrozova, O. Steichen, and L. Amar Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study Hypertension 53 2009 605 610
82. P. Farahnak, G. Larfars, M. Sten-Linder, and I.L. Nilsson Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers J Clin Endocrinol Metab 96 2011 2112 2118
83. P. Luigi, F.M. Chiara, and Z. Laura Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: preliminary results Int J Endocrinol 2012 2012 408295
84. H. Schiffl, and S.M. Lang Hypertension secondary to PHPT: cause or coincidence? Int J Endocrinol 2011 2011 974647
85. R. Pacifici, H.M. Perry III, and W. Shieber Adrenal responses to subtotal parathyroidectomy for primary hyperparathyroidism Calcif Tissue Int 41 1987 119 123
86. G.P. Rossi Hyperparathyroidism, arterial hypertension and aortic stiffness: a possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage? Hypertens Res 34 2011 286 288
87. A. Ishay, P. Herer, and R. Luboshitzky Effects of successful parathyroidectomy on metabolic cardiovascular risk factors in patients with severe primary hyperparathyroidism Endocr Pract 17 2011 584 590
88. L. Brunaud, A. Germain, and R. Zarnegar Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism Surgery 146 2009 1035 1041
89. P. Vestergaard, and L. Mosekilde Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism BMJ 327 2003 530 534
90. G. Bernini, A. Moretti, and S. Lonzi Renin-angiotensin-aldosterone system in primary hyperparathyroidism before and after surgery Metabolism 48 1999 298 300
91. A. Tomaschitz, A. Fahrleitner-Pammer, and B. Pieske Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial BMC Endocr Disord 12 2012 19
92. F. Koiwa, D. Komukai, and M. Hirose Influence of renin-angiotensin system on serum parathyroid hormone levels in uremic patients Clin Exp Nephrol 16 2012 130 135
93. M.R. Rutledge, V. Farah, and A.A. Adeboye Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism Cardiovasc Drugs Ther 27 2013 161 170
94. A.L. Runyan, V.S. Chhokar, and Y. Sun Bone loss in rats with aldosteronism Am J Med Sci 330 2005 1 7
95. V.S. Chhokar, Y. Sun, and S.K. Bhattacharya Loss of bone minerals and strength in rats with aldosteronism Am J Physiol Heart Circ Physiol 287 2004 H2023 H2026
96. P.H. Law, Y. Sun, and S.K. Bhattacharya Diuretics and bone loss in rats with aldosteronism J Am Coll Cardiol 46 2005 142 146
97. M. Yamamoto, T. Yamaguchi, and M. Yamauchi Acute-onset hypomagnesemia-induced hypocalcemia caused by the refractoriness of bones and renal tubules to parathyroid hormone J Bone Miner Metab 29 2011 752 755
98. V.S. Chhokar, Y. Sun, and S.K. Bhattacharya Hyperparathyroidism and the calcium paradox of aldosteronism Circulation 111 2005 871 878
99. L.D. Carbone, J.D. Cross, and S.H. Raza Fracture risk in men with congestive heart failure risk reduction with spironolactone J Am Coll Cardiol 52 2008 135 138
100. G. Kamalov, R.A. Ahokas, and W. Zhao Uncoupling the coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria seen in aldosteronism J Cardiovasc Pharmacol 55 2010 248 254
101. R.N. Khouzam, D.A. Dishmon, and V. Farah Secondary hyperparathyroidism in patients with untreated and treated congestive heart failure Am J Med Sci 331 2006 30 34
102. S. Alsafwah, S.P. Laguardia, and M.D. Nelson Hypovitaminosis D in African Americans residing in Memphis, Tennessee with and without heart failure Am J Med Sci 335 2008 292 297
103. Y. Cheema, J.N. Sherrod, and W. Zhao Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol J Cardiovasc Pharmacol 58 2011 80 86
104. A.P. Halestrap Calcium, mitochondria and reperfusion injury: a pore way to die Biochem Soc Trans 34 2006 232 237
105. F.P. Cappuccio, N.D. Markandu, and G.A. MacGregor Renal handling of calcium and phosphate during mineralocorticoid administration in normal subjects Nephron 48 1988 280 283
106. M.K. Gehr, and M. Goldberg Hypercalciuria of mineralocorticoid escape: clearance and micropuncture studies in the rat Am J Physiol 251 1986 F879 F888
107. W.N. Suki Disposition and regulation of body potassium: an overview Am J Med Sci 272 1976 31 41
108. J. Lemann Jr., W.F. Piering, and E.J. Lennon Studies of the acute effects of aldosterone and cortisol on the interrelationship between renal sodium, calcium and magnesium excretion in normal man Nephron 7 1970 117 130
109. O. Skott, T.R. Uhrenholt, and J. Schjerning Rapid actions of aldosterone in vascular health and disease - friend or foe? Pharmacol Ther 111 2006 495 507
110. S. Morizane, F. Mitani, and K. Ozawa Biphasic time course of the changes in aldosterone biosynthesis under high-salt conditions in Dahl salt-sensitive rats Arterioscler Thromb Vasc Biol 32 2012 1194 1203
111. M.G. Tordoff NaCl ingestion ameliorates plasma indexes of calcium deficiency Am J Physiol 273 1997 R423 R432
112. J.G. Hoenderop, and R.J. Bindels Epithelial Ca2 + and Mg2 + channels in health and disease J Am Soc Nephrol 16 2005 15 26
113. D.K. Atchison, P. Harding, and W.H. Beierwaltes Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor Hypertension 58 2011 604 610
114. R.L. McCarron DA, and W.M. Bennett Urinary calcium excretion at extremes of sodium intake in normal man Am J Nephrol 1 1981 84 90
115. E. Rossi, F. Perazzoli, and A. Negro Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects with essential hypertension Am J Hypertens 11 1998 8 13
116. G.P. Rossi, G. Bernini, and C. Caliumi A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients J Am Coll Cardiol 48 2006 2293 2300
117. A. Tomaschitz, W. Maerz, and S. Pilz Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range J Am Coll Cardiol 55 2010 2171 2180
118. G.P. Rossi, V. Di Bello, and C. Ganzaroli Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism Hypertension 40 2002 23 27
119. L.A. Sechi, M. Novello, and R. Lapenna Long-term renal outcomes in patients with primary aldosteronism J Am Med Assoc 295 2006 2638 2645
120. L.M. Resnick, F.B. Muller, and J.H. Laragh Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism Ann Intern Med 105 1986 649 654
121. L.M. Resnick, and J.H. Laragh Calcium metabolism and parathyroid function in primary aldosteronism Am J Med 78 1985 385 390
122. U.M. Kabadi Renal calculi in primary hyperaldosteronism J Postgrad Med 41 1995 17 18
123. E. Rossi, C. Sani, and F. Perazzoli Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas Am J Hypertens 8 1995 884 893
124. S. Pilz, A. Tomaschitz, and W. März Aldosterone and parathyroid hormone: a complex and clinically relevant relationship Calcif Tissue Int 87 2010 373 374
125. S. Pilz, A. Tomaschitz, and V. Stepan Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism BMC Endocr Disord 9 2009 11
126. S. Pilz, K. Kienreich, and C. Drechsler Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study J Clin Endocrinol Metab 97 2012 E75 E79
127. C. Maniero, A. Fassina, and T.M. Seccia Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism J Hypertens 30 2012 390 395
128. G.P. Rossi, F. Ragazzo, and T.M. Seccia Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma Hypertension 60 2012 431 436
129. S. Beavan, A. Horner, and S. Bord Colocalization of glucocorticoid and mineralocorticoid receptors in human bone J Bone Miner Res 16 2001 1496 1504
130. A. Vidal, Y. Sun, and S.K. Bhattacharya Calcium paradox of aldosteronism and the role of the parathyroid glands Am J Physiol Heart Circ Physiol 290 2006 H286 H294
131. M. Gupta, C.L. Cheung, and Y.H. Hsu Identification of homogeneous genetic architecture of multiple genetically correlated traits by block clustering of genome-wide associations J Bone Miner Res 26 2011 1261 1271
132. A.S. Salcuni, S. Palmieri, and V. Carnevale Bone involvement in aldosteronism J Bone Miner Res 27 2012 2217 2222
133. L. Ceccoli, V. Ronconi, and L. Giovannini Bone health and aldosterone excess Osteoporos Int 2013 10.1007/s00198-013-2399-1
134. J. Fuentes, P.M. Guerreiro, and T. Modesto A PTH/PTHrP receptor antagonist blocks the hypercalcemic response to estradiol-17beta Am J Physiol Regul Integr Comp Physiol 293 2007 R956 R960